Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a virtual program and wearable sensor tame type 2 diabetes?

NCT ID NCT07743307

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 27, 2026 · Updated 3 times

Summary

This study tests whether combining a virtual diabetes self-management program with continuous glucose monitoring is practical and well-liked by adults with type 2 diabetes. Twenty participants will attend a 9-week virtual program and wear a glucose sensor for up to 22 weeks to track blood sugar. They will fill out questionnaires and have blood drawn to measure long-term blood sugar control. The goal is to see if this integrated approach could lead to better diabetes management and improved health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A virtual diabetes self-management program (DECIDE) combined with continuous glucose monitoring (Freestyle Libre)
What this could lead to
If this approach proves practical and acceptable, it could lead to a new way to help adults with type 2 diabetes better manage their blood sugar and improve health outcomes.
What could go wrong
This is a small feasibility study with only 20 participants, so results may not apply broadly. The program requires consistent participation and CGM use, which may be challenging for some.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older * Diagnosis of type 2 diabetes * Suboptimal hemoglobin A1C (8.0% or greater) based on a laboratory result in the past 3 months * Access to and capability of using a smart cellular device * Smart cellular device compatible with the Freestyle Libre CGM smartphone application * Capable of giving informed consent Exclusion Criteria: * Currently using CGM * Non-English speaking * Unavailable to attend the virtual DECIDE group * Unavailable for follow-up * Currently pregnant * Currently on dialysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Northwell Heath

    Manhasset, New York, 11030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.